Navigation Links
Grand Challenges in Global Health initiative funds Yale project

Yale has been offered $17 million from the Grand Challenges in Global health initiative to genetically engineer mice with immune systems similar enough to humans to aid in testing the safety and effectiveness of potential vaccines.

Funded by the Bill & Melinda Gates Foundation, the Yale project will be headed by Richard A. Flavell, M.D., Sterling Professor and Chair of Immunobiology at Yale University School of Medicine, and Howard Hughes Medical Institute investigator.

Flavell and his team will study a novel solution to a problem facing many vaccine developers. Some of the most promising vaccines for HIV and a range of other diseases are made from weakened versions of the infectious agent. These cannot be studied in human trials unless researchers are confident that they are safe.

"A big need in the world of vaccine development is the ability to predict whether vaccines for humans are safe and effective," said Flavell. "We are grateful to the Grand Challenges in Global Health Initiative for providing the funds to develop a predictive model system for vaccine testing."

Yale School of Medicine Dean Robert Alpern, M.D., said, "This generous grant from the Grand Challenges in Global Health Initiative provides a boost to Yale's ongoing initiatives in basic science and clinical research. It will advance research on diseases that have an effect on communities worldwide."

The goal of this award is to provide to the research community a suitable model system to test live attenuated vaccines for use in the developing world. Flavell said the mice generated would be made available to the broader scientific community in order to meet the charitable objectives of the Grand Challenges Initiative. Flavell will collaborate with the Institute for Research in Biomedicine in Switzerland and with Regeneron Pharmaceuticals in Tarrytown, New York.

The team will engineer a mouse model in which critical components of the human immune syste m replace the similar regions of the mouse. A new technology developed at the Institute for Research in Biomedicine introduces cells from human umbilical cord blood into mice to establish a human immune system. "Using this technology and the genetic modification of the mouse, we will end up with a reasonably faithful replica of the human immune system," said Flavell.

The project is titled "A Mouse Model to Evaluate Live-Attenuated Vaccine Candidates."


'"/>

Source:Yale University


Related biology news :

1. Measurement Challenges In Detecting Cancer Biomarkers
2. Global analysis of membrane proteins
3. Global warming increases oyster sensitivity to pollution
4. Global study shows all tobacco bad for the heart
5. Global warming may warrant new approaches to ecosystem restoration
6. Global warming may have damaged coral reefs forever
7. Global malaria map key weapon in fight against malaria, scientists say
8. Global changes alter the timing of plant growth, scientists say
9. Global map shows new patterns of extinction risk
10. Global sunscreen has likely thinned, report NASA scientists
11. Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology: